Mesenchymal stem/stromal cells: A new "cells as drugs" paradigm. efficacy and critical aspects in cell therapy

Laura de Girolamo, Enrico Lucarelli, Giulio Alessandri, Maria Antonietta Avanzini, Maria Ester Bernardo, Ettore Biagi, Anna Teresa Brini, Giovanna D'Amico, Franca Fagioli, Ivana Ferrero, Franco Locatelli, Rita Maccario, Mario Marazzi, Ornella Parolini, Augusto Pessina, Maria Luisa Torre

Research output: Contribution to journalArticle

114 Scopus citations

Abstract

Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.

Original languageEnglish (US)
Pages (from-to)2459-2473
Number of pages15
JournalCurrent Pharmaceutical Design
Volume19
Issue number13
DOIs
StatePublished - 2013

Keywords

  • Advanced therapy medicinal product
  • Cell therapy
  • Graft versus host disease
  • Immunomodulatory properties
  • MSCs sources
  • Mesenchymal stem/stromal cells
  • Regenerative medicine
  • Transplantation

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Mesenchymal stem/stromal cells: A new "cells as drugs" paradigm. efficacy and critical aspects in cell therapy'. Together they form a unique fingerprint.

Cite this